Ipsen Pharma

Industry / private company


Location: Paris, etc., France (FR) FR

ISNI: 0000000119574504

ROR: https://ror.org/00d801g55

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS (2018) Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, et al. Journal article Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study (2018) Pavel ME, Denecke T, Lahner H, Hoersch D, Rinke A, Koch A, Liyanage N, et al. Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension (2017) Cwikla JB, Wolin EM, Pavel ME, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution
‹ 1 2 3 4 ›